Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02303015
Other study ID # DaTeCa01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 2014
Est. completion date June 2023

Study information

Verified date November 2023
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to identify genetic variations in survivors of testicular cancer and connect these variations to differences in risks of late effects.


Description:

Identification of late-effects through questionnaires and linkage to national registries. DNA samples will be gathered through buccal swabs or saliva kits and analysed with whole exome-sequencing.


Recruitment information / eligibility

Status Completed
Enrollment 430
Est. completion date June 2023
Est. primary completion date March 2023
Accepts healthy volunteers No
Gender Male
Age group 15 Years and older
Eligibility Inclusion Criteria: - Danish citizen - Diagnosed with germ cell cancer from 1984 to 2007 - Treated initially at a Danish hospital - Treated with standard treatment regimens. Exclusion Criteria: - Treated initially at a foreign hospital

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Denmark Dept. of Oncology, Rigshospitalet Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Renal toxicity (Identify genetic variations predicting renal toxicity) Identify genetic variations predicting renal toxicity. 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00996710 - Genomic Structural Variation in Cancer Susceptibility
Active, not recruiting NCT01453660 - Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls
Completed NCT01242631 - Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer Phase 2
Completed NCT01851200 - Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors Phase 2
Not yet recruiting NCT06275854 - YASU Research Registry: For Young Adults With Cancer
Recruiting NCT04897321 - B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) Phase 1
Not yet recruiting NCT06329323 - SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours